Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APX005M with Chemoradiation for Esophageal/GEJ Cancer
NCT03165994Phase 2Completed
- Sponsor
- Apexigen, Inc.
- Start
- Oct 2017
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sotigalimab in esophageal cancer, gastroesophageal junction cancer, sponsored by Apexigen, Inc.. Started Oct 2017; status: completed.
02
Drugs
sotigalimab
03
Conditions
esophageal cancergastroesophageal junction cancer
Beyond the preview
Go deeper on NCT03165994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03165994.